Metformin and insulin sensitizers vs Insulin secretagogues, incretin drugs, and SGLT2 inhibitors
How to tell Metformin and insulin sensitizers and Insulin secretagogues, incretin drugs, and SGLT2 inhibitors apart when a board question makes them look alike.
Metformin lowers liver glucose output; sulfonylureas force insulin; incretin drugs are glucose-dependent; SGLT2 drugs spill glucose into urine.
Side by side
Metformin decreases hepatic gluconeogenesis; thiazolidinediones activate PPAR-gamma but can cause edema and weight gain.
Sulfonylureas increase insulin release, GLP-1/DPP-4 amplify incretin signaling, and SGLT2 inhibitors cause glycosuria.
Insulin sensitizer pattern improves response to insulin without forcing direct insulin release.
Other diabetes drugs either increase insulin secretion, amplify glucose-dependent incretins, or waste glucose in urine.
Metformin GI effects or lactic acidosis risk; thiazolidinedione edema/heart failure risk.
Sulfonylurea hypoglycemia, GLP-1 weight loss, DPP-4 weight neutrality, or SGLT2 genital infections identify the subgroup.
The trap
All lower glucose, so hypoglycemia risk, weight direction, and kidney glycosuria clues separate them.
The repair move
For diabetes drugs, first ask whether insulin is forced, sensitized, incretin-amplified, or bypassed through urinary glucose loss.
Try a free question
CoreA patient with type 2 diabetes starts a first-line drug that reduces hepatic gluconeogenesis and can cause GI upset and lactic acidosis risk in renal failure. Which drug is most likely?
Show answer and explanation
Answer: A. Metformin. Metformin decreases hepatic glucose production and is the classic first-line insulin-sensitizing drug.
Why the other choices are tempting
- B. Sulfonylureas increase insulin release and can cause hypoglycemia and weight gain.
- C. Thiazolidinediones activate PPAR-gamma and can cause edema and weight gain.
- D. SGLT2 inhibitors cause glycosuria and increase genital infection risk.
- E. DPP-4 inhibitors increase endogenous incretin activity and are generally weight neutral.
Flashcards
Tap a card to flip it.
What is the fastest separator for Metformin and insulin sensitizers vs Insulin secretagogues, incretin drugs, and SGLT2 inhibitors?
Metformin lowers liver glucose output; sulfonylureas force insulin; incretin drugs are glucose-dependent; SGLT2 drugs spill glucose into urine.
What clue should make you choose Metformin and insulin sensitizers?
Metformin decreases hepatic gluconeogenesis; thiazolidinediones activate PPAR-gamma but can cause edema and weight gain.
Quick answers
What is the fastest way to tell Metformin and insulin sensitizers from Insulin secretagogues, incretin drugs, and SGLT2 inhibitors?
Metformin lowers liver glucose output; sulfonylureas force insulin; incretin drugs are glucose-dependent; SGLT2 drugs spill glucose into urine.
What is the key clue for Metformin and insulin sensitizers?
Metformin decreases hepatic gluconeogenesis; thiazolidinediones activate PPAR-gamma but can cause edema and weight gain.
What is the key clue for Insulin secretagogues, incretin drugs, and SGLT2 inhibitors?
Sulfonylureas increase insulin release, GLP-1/DPP-4 amplify incretin signaling, and SGLT2 inhibitors cause glycosuria.
What is the common trap with Metformin and insulin sensitizers vs Insulin secretagogues, incretin drugs, and SGLT2 inhibitors?
All lower glucose, so hypoglycemia risk, weight direction, and kidney glycosuria clues separate them.